niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

Lynparza cleared for first-line ovarian cancer use in China

GlaxoSmithKline. GSK’s rival drug Zejula (niraparib) is also closing in on the first-line ovarian cancer setting – it recently presented positive findings in this indication at the European Society of

Latest news

GSK gets FDA okay for wider use of PARP drug Zejula

The US regulator has approved Zejula (niraparib) as a fourth-line treatment for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer associated with a type of mutation known as
J&J bags FDA breakthrough designation for prostate cancer drug

Lynparza. . J&J’s pharmaceutical division Janssen has exclusive rights to niraparib in prostate cancer. ... Patients must have received prior taxane chemotherapy and androgen receptor (AR)-targeted therapy prior to beginning niraparib treatment.
Lynparza scores another positive phase 3 prostate cancer study

The results also continue to build the case that Lynparza is leading the PARP inhibtor category, as it competes with Clovis Oncology’s Rubraca (rucaparib), GlaxoSmithKline/Tesaro’s Zejula (niraparib) and
GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

However, GSK also brought positive findings for Zejula (niraparib) in ovarian cancer, with the potential benefit that it is a monotherapy.
Trial backs role for Lynparza in second-line prostate cancer

niraparib) and Pfizer’s Talzenna (talazoparib).

More from news
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.